Impact of Hybrid-ESD+ and LiftUp® on the en Bloc/R0 Rate in Colorectal Adenomas Between 2 and 3 cm
NCT ID: NCT05517369
Last Updated: 2023-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2023-03-01
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hybrid Versus Non-Hybrid Endoscopic Submucosal Dissection for Colorectal Polyps (SHORT-ESD)
NCT05347446
Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial
NCT01913223
Full Thickness Resection or Endoscopic Submucosal Dissection for Difficult Colorectal Lesions.
NCT05502276
Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy
NCT01879904
Piecemeal Versus En Bloc Resection of Large Rectal Adenomas
NCT02238938
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conventional EMR has the disadvantage of more frequent residuals and/or recurrences due to lack of en bloc resection, while ESD has the disadvantage of being more complex and complications more likely.
A possible alternative is the use of hybrid ESD+ with LiftUp subcutaneous injection. The method with the LiftUp gel forming a stable gel cushion under the lesion, in combination with the circular circumcision of the mucosa at this site and the AWC for the current loop and the grasper, could achieve a better en bloc resection rate with a low complication rate than other procedures mentioned above.
The higher effectiveness in terms of recurrences and complications could subsequently result in a reduction of endoscopic or surgical re-interventions.
In this study, non-pedunculated colorectal polyps between 2 and 3cm in size are resected using ESD+ method and lift up as an injection solution.
Methodological and clinical parameters are recorded. After 4 weeks, the patients are contacted by telephone to record possible late effects.
If an endoscopic control is performed after 6 months (according to the guideline or according to the investigator), the findings are also recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hybrid-ESD+
All participants receive resection of non-pedunculated colorectal polyp between 2 and 3 cm using the Hybrid-ESD+ method.
Hybrid ESD+
Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hybrid ESD+
Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ablation medically indicated and possible (coagulation, etc. - as determined by the center)
Exclusion Criteria
* Pedunculated lesion (Paris0-Ip)
* Size of the lesion \<2cm or \>3cm
* Pregnant and breastfeeding women
* Patient not capable of informed consent / consent not possible
* Bioptic evidence of a carcinoma / high probability of the presence of a carcinoma
* Non-lifting sign / known recurrence after previous therapy
* Impassable stenosis in the colon / rectum
* Patients with compelling need for therapeutic anticoagulation or dual antiplatelet therapy that cannot be discontinued for resection
* As per contraindications from the AWC \& LiftUp Instructions for Use:
* The AWC is not to be used if flexible-endoscopic procedures are contraindicated.
* The LiftUp gel should not be used when flexible endoscopic procedures are contraindicated, especially in combination with submucosal endoscopic resection (EMR) or endoscopic submucosal dissection (ESD) injectables.
* LiftUp gel should not be used in patients with known sensitivity to any of the ingredients.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Waid City Hospital, Zurich
OTHER
University Hospital Ulm
OTHER
Rems-Murr-Klinikum Winnenden
UNKNOWN
Insel Gruppe AG, University Hospital Bern
OTHER
Klinikum Ludwigsburg
OTHER
Mathilden Hospital Herford
UNKNOWN
St. Franziskus Hospital Münster
UNKNOWN
Agaplesion Kliniken Kassel
UNKNOWN
Ovesco Endoscopy AG
INDUSTRY
Wuerzburg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mathilden Hospital Herford
Herford, , Germany
Agaplesion Diakonie Kliniken Kassel
Kassel, , Germany
Klinikum Ludwigsburg
Ludwigsburg, , Germany
St. Franziskus Hospital Münster
Münster, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Rems-Murr-Klinikum Winnenden
Winnenden, , Germany
Universitätsklinik Würzburg
Würzburg, , Germany
Inselspital Bern
Bern, , Switzerland
Stadtspital Waid
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WHO Universal Trail Number
Identifier Type: OTHER
Identifier Source: secondary_id
Brand_HADRIAN_10_08_2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.